Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2024-09-16 am EDT			5-day change	1st Jan Change
922.10 ^DKK	+0.39%		+3.96%	+32.09%

03:11pm	Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	MT
02:00pm	Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	CI

NOVO NORDISK : Goldman Sachs reiterates its Buy rating

July 11, 2024 at 04:05 am EDT

In a research note published by James Quigley, Goldman Sachs advises its customers to buy the stock. The target price remains unchanged at DKK 1070.

Latest news about Novo Nordisk A/S

Korro Bio Partners With Novo Nordisk to Develop Genetic Medicines	09:11am	MT
Korro Bio, Inc Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates	08:00am	CI
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	Sep. 12	RE
NOVO NORDISK : Deutsche Bank keeps its Buy rating	Sep. 12	ZD
Roche shares drop on side effects result in early-stage obesity pill trial	Sep. 12	RE
Health Care Down on Cyclical Bias -- Health Care Roundup	Sep. 11	DJ
Sector Update: Health Care Stocks Narrowly Mixed Premarket Wednesday	Sep. 11	MT
Novo Nordisk's Experimental Obesity Pill Could Be More Effective With Extended Use	Sep. 11	DJ
NOVO NORDISK : JP Morgan reiterates its Buy rating	Sep. 11	ZD
NOVO NORDISK : Gets a Neutral rating from UBS	Sep. 11	ZD
Novo Nordisk Reports Positive Results of Phase 3a Trial of Anti-Obesity Drug Liraglutide in Children	Sep. 11	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Sep. 10	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	Sep. 10	RE
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	Sep. 06	MT
Novo Nordisk to present advances in diabetes treatment	Sep. 06	CF
Are thematic ETFs useless?	Sep. 06
Veeva Systems: leader in cloud solutions for the life sciences industry	Sep. 06
NOVO NORDISK : Gets a Neutral rating from Berenberg	Sep. 06	ZD
Health Care Declines as Risk Aversion Weighs - Health Care Roundup	Sep. 05	DJ
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	Sep. 05	MT
NOVO NORDISK : JP Morgan remains its Buy rating	Sep. 05	ZD
How to find and check an Ozempic batch number	Sep. 05	RE
Ozempic shortages will hit some EU countries only - Novo Nordisk	Sep. 04	RE
Ozempic shortages in EU will not affect all member states - Novo Nordisk	Sep. 04	RE
US will still pay at least twice as much after negotiating drug prices	Sep. 03	RE

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Employees

69,260

Sector

Pharmaceuticals

Calendar

2024-11-06 - Q3 2024 Earnings Release

More about the company